posted on 2019-06-17, 05:00authored byNoah Berlow, Rishi Rikhi, Mathew Geltzeiler, Jinu Abraham, Matthew Svalina, Lara Davis, Erin Wise, Maria Mancini, Jonathan Noujaim, Atiya Mansoor, Michael Quist, Kevin Matlock, Martin Goros, Brian Hernandez, Yee Doung, Khin Thway, Tomohide Tsukahara, Jun Nishio, Elaine Huang, Susan Airhart, Carol Bult, Regina Gandour-Edwards, Robert Maki, Robin Jones, Joel Michalek, Milan Milovancev, Souparno Ghosh, Ranadip Pal, Charles Keller
Figure S7. Probabilistic Target Inhibition Map (PTIM) model of U23674 Roche chemical screen hits. Values in the center of PTIM blocks represent expected scaled sensitivity following inhibition of associated block targets. (A) Base chemical screen informed PTIM. (B) RNA-seqâ+âchemical screen informed PTIM. Roche screen hits include CDK2 inhibitors. However, no CDK inhibitor was a known inhibitor of non-CDK targets, limiting development of personalized combinations involving CDK inhibitors. (TIF 29510 kb)